Sometimes facts lie. More specifically, they don't tell the whole truth. Implant Sciences' (OTCQB:IMSC) third quarter and nine month results showed dramatic gains in revenues, 84 percent in Q3, 237 percent for the nine month period. On the face of it, exceptional.
However, the company also reported a net loss for the third quarter of $5.3 million compared to $3.9 the prior year, and a net loss of $21.8 million for the nine month period compared to a net loss of $10.3 million the prior nine months. On the face of it, depressing.
So what is it!? Does rapid top line growth indicate the company will shortly turn the corner to profitability? Or will bottom line...
Only subscribers can access this article, which is part of the PRO research library covering 3,582 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: